Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?

Details

Serval ID
serval:BIB_E43D2D4A7F83
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Title
Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?
Journal
Biomarkers in Medicine
Author(s)
Sasaroli D., Coukos G., Scholler N.
ISSN
1752-0371 (Electronic)
ISSN-L
1752-0363
Publication state
Published
Issued date
2009
Volume
3
Number
3
Pages
275-288
Language
english
Notes
Publication types: JOURNAL ARTICLEPublication Status: ppublish
Abstract
Ovarian cancer (OC) is the fourth leading cause of cancer deaths among women in the United States, despite its relatively low incidence of 50 per 100,000. Even though advances in therapy have been made, the OC fatality-to-case ratio remains exceedingly high, due to the lack of accurate tools to diagnose early-stage disease when cure is still possible. The most studied marker for OC, CA125, is only expressed by 50-60% of patients with early stage disease. Large efforts have been deployed to identify novel serum markers, yet no single marker has emerged as a serious competitor for CA125. Various groups are investing in combination approaches to increase the diagnostic value of existing markers, but many markers may still lie in under-explored areas of ovarian cancer biology, such as tumor vasculature environment and post-translational modifications (glycomics).
Pubmed
Create date
14/10/2014 11:43
Last modification date
20/08/2019 16:07
Usage data